Skip to content

{ Tag Archives } Medicine

SANUWAVE’s PACE Technology Is A Novel, Safe And Cost-Effective Method To Treat Severe Burns Without Surgery Or Skin Grafting

SANUWAVE Health, Inc., (OTC BB: SNWV), an emerging medical technology company focused on regenerative medicine, announced that a European scientific study reporting the successful treatment of severe burns using the dermaPACE® device has been published by BURNS, the Journal of the International Society for Burn Injuries…

Bookmark and Share Also tagged , , , , , , , , , ,

Sutures Cause Fewer Complications Than Staples With Cesarean Deliveries

In a study presented at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™ in Chicago, researchers presented findings that there were less complications for women, after having a cesarean delivery, if sutures were used instead of staples to close the wound. When Suzanne Basha, M.D…

Bookmark and Share Also tagged , , , , , , , , , ,

STELARA(TM) Shows Greater Efficacy Than Etanercept For Treatment Of Moderate To Severe Plaque Psoriasis

Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear in The New England Journal of Medicine. The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week [...]

Bookmark and Share Also tagged , , , , , , , , , , , , ,

New Study Published In The New England Journal Of Medicine Shows Superiority Of CareFusion ChloraPrep(R) Compared To Povidone Iodine

Data published in The New England Journal of Medicine demonstrates that use of CareFusion’s patient preoperative skin preparation ChloraPrep® (2 percent chlorhexidine gluconate and 70 percent isopropyl alcohol) reduced total surgical site infections (SSIs) by 41 percent, from 16.1 percent to 9…

Bookmark and Share Also tagged , , , , , , , , , , , ,

Excaliard Initiates Phase 2 Trials In U.S. For Its Skin Scarring Drug, EXC 001

Excaliard Pharmaceuticals, Inc. announced the initiation of three proof of concept Phase 2 trials of EXC 001, an antisense medicine that reduces fibrosis, for the amelioration of skin scarring and other fibrotic disorders. The U.S…

Bookmark and Share Also tagged , , , , , , , ,

Study Redefines Placebo Effect As Part Of Effective Treatment

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine…

Bookmark and Share Also tagged , , , ,

Study Redefines Placebo Effect As Part Of Effective Treatment

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to an early study published online today in the journal Psychosomatic Medicine…

Bookmark and Share Also tagged , , , ,

Skin’s Healthy Balance Maintained By Surface Bacteria

On the skin’s surface, bacteria are abundant, diverse and constant, but inflammation is undesirable. Research at the University of California, San Diego School of Medicine now shows that the normal bacteria living on the skin surface trigger a pathway that prevents excessive inflammation after injury. “These germs are actually good for us,” [...]

Bookmark and Share Also tagged , , , , , , , , , ,

More News Briefs From Plastic Surgery 2009

Face and Hand Transplants – Ready to Become Mainstream Medicine? Though once inconceivable, face and hand transplants are quickly making themselves more present, both in the operating room and in the media. The world’s first hand transplant was performed more than a decade ago, and the first partial-face transplant performed [...]

Bookmark and Share Also tagged , , , , , , , , ,

Arpida A/S Withdraws Its Marketing Authorisation Application For Mersarex (iclaprim), Europe

The European Medicines Agency has been formally notified by Arpida A/S of its decision to withdraw its application for a centralised marketing authorisation for the medicine Mersarex (iclaprim), 12.8 mg/ml concentrate for solution for infusion. Mersarex was expected to be used for the treatment of complicated skin and soft tissue infections. [...]

Bookmark and Share Also tagged , , , , , , ,